Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Adalimumab is effective for both remission induction and the maintenance of Crohn’s disease (CD) in Western countries. We evaluated the efficacy of adalimumab in the conventional step-up treatment approach for CD in Korea. Methods: We retrospectively reviewed 62 patients with CD who were treated with adalimumab. Their Crohn’s disease activity index (CDAI) was measured at weeks 4, 8, and 52. Clinical remission was defined as a CDAI score <150. Induction and maintenance outcomes were analyzed. Results: Forty-one patients (66.1%) achieved a reduction of 70 CDAI points at week 8. Among them, 28 (45.2%) achieved clinical remission at week 8, 20 (32.3%) maintained remission at week 52. The absence of prior anti-tumor necrosis factor (TNF) therapy and Montreal classification L1 at baseline predicted clinical remission at week 8 in the multivariate logistic regression analysis. In the Cox proportional hazards model, the hazard ratio for the secondary loss of response during maintenance therapy after clinical remission induction was significantly higher in patients who showed initial mild CDAI severity or Montreal classification A3. Conclusions: In our study, anti-TNF therapy-naive and Montreal classification L1 were associated with adalimumab efficacy as induction therapy in CD. Further studies are warranted to determine the prognostic factors for the long-term response after adalimumab therapy.
Abstract
Background/Aims: Adalimumab is effective for both remission induction and the maintenance of Crohn’s disease (CD) in Western countries. We evaluated the efficacy of adalimumab in the conventional step-up treatment approach for CD in Korea. Methods: We retrospectively reviewed 62 patients with CD who were treated with adalimumab. Their Crohn’s disease activity index (CDAI) was measured at weeks 4, 8, and 52. Clinical remission was defined as a CDAI score <150. Induction and maintenance outcomes were analyzed. Results: Forty-one patients (66.1%) achieved a reduction of 70 CDAI points at week 8. Among them, 28 (45.2%) achieved clinical remission at week 8, 20 (32.3%) maintained remission at week 52. The absence of prior anti-tumor necrosis factor (TNF) therapy and Montreal classification L1 at baseline predicted clinical remission at week 8 in the multivariate logistic regression analysis. In the Cox proportional hazards model, the hazard ratio for the secondary loss of response during maintenance therapy after clinical remission induction was significantly higher in patients who showed initial mild CDAI severity or Montreal classification A3. Conclusions: In our study, anti-TNF therapy-naive and Montreal classification L1 were associated with adalimumab efficacy as induction therapy in CD. Further studies are warranted to determine the prognostic factors for the long-term response after adalimumab therapy.
참고문헌 (22)
- 이양운, "Clinical and Endoscopic Recurrence after Surgical Resection in Patients with Crohn’s Disease", Intestinal research, 12(2), pp.117~123 (2014), 대한장연구학회
- Park SJ, "Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives", World J Gastroenterol, 20, pp.11525~11537 (2014)
- Schnitzler F, "Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease:results from a single-centre cohort", Gut, 58, pp.492~500 (2009)
- Nanda KS, "Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis", Am J Gastroenterol, 108, pp.40~47 (2013)
- Hanauer SB, "Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease:the CLASSIC-I trial", Gastroenterology, 130, pp.323~333 (2006)
- Colombel JF, "Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial", Gastroenterology, 132, pp.52~65 (2007)
- Sandborn WJ, "Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial", Gut, 56, pp.1232~1239 (2007)
- Sandborn WJ, "Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial", Ann Intern Med, 146, pp.829~838 (2007)
- Chen-Wang Chang, "Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn’s Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study", Intestinal research, 12(4), pp.287~292 (2014), 대한장연구학회
- Silverberg MS, "Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology", Can J Gastroenterol, 19(A), pp.5A~36A (2005)
- Van Assche G, "The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis", J Crohns Colitis, 4, pp.7~27 (2010)
- Yanai H, "Assessing response and loss of response to biological therapies in IBD", Am J Gastroenterol, 106, pp.685~698 (2011)
- Singh S, "Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network metaanalysis", Mayo Clin Proc, 89, pp.1621~1635 (2014)
- Karmiris K, "Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease", Gastroenterology, 137, pp.1628~1640 (2009)
- 김은수, "Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, Clinical, and Therapeutic Characteristics", Gut and Liver, 4(1), pp.1~14 (2010), 거트앤리버 발행위원회
- 양동훈, "Usefulness of C-Reactive Protein as a Disease Activity Marker in Crohn’s Disease according to the Location of Disease", Gut and Liver, 9(1), pp.80~86 (2015), 거트앤리버 발행위원회
- Panaccione R, "Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment:data from CHARM and ADHERE", Aliment Pharmacol Ther, 38, pp.1236~1247 (2013)
- Billioud V, "Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review", Am J Gastroenterol, 106, pp.674~684 (2011)
- Ferrante M, "Physician perspectives on unresolved issues in the use of conventional therapy in Crohn’s disease: results from an international survey and discussion programme", J Crohns Colitis, 6, pp.116~131 (2012)
- Toruner M, "Risk factors for opportunistic infections in patients with inflammatory bowel disease", Gastroenterology, 134, pp.929~936 (2008)
- Peyrin-Biroulet L, "Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: metaanalysis of placebo-controlled trials", Clin Gastroenterol Hepatol, 6, pp.644~653 (2008)
- Jones J, "Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease", Clin Gastroenterol Hepatol, 6, pp.1218~1224 (2008)